The aim of study was aimed to investigate associations of platelet-to-neutrophil ratio (PNR) and platelet-to-lymphocyte ratio (PLR) on admission with clinical outcomes of patients with aneurysmal subarachnoid hemorrhage (aSAH). A retrospective analysis was performed on patients who were treated for aSAH. Unfavorable clinical outcome was defined as Modified Rankin Scale (mRS) score of 3–6 at 90-days. Receiver operating characteristic curve analysis was performed to detect optimal cutoff values of PNR and PLR for predicting clinical outcomes. Logistic regression was used to explore associations of PNR and PLR with clinical outcomes. A total of 544 patients with aSAH were enrolled. Of them, 152 (29.9%) had unfavorable clinical outcome. Optimal cutoff values of PNR and PLR to predict clinical outcomes at 90 days after aSAH were 25 and 130, respectively (P < 0.001 and <0.001, respectively). In multivariate logistic regression analysis, PNR <25 and PLR ≥ 130 were associated with unfavorable clinical outcome at 90 days after aSAH (odds ratio [OR]: 1.81; 95% confidence interval [CI]: 1.23–3.69; P = 0.018 and OR: 1.56; 95% CI: 1.18–2.62; P = 0.031, respectively). PNR and PLR as novel inflammatory biomarkers could predict the clinical outcome after aSAH. PNR <22 and PLR ≥ 130 were associated with unfavorable clinical outcome at 90 days after aSAH.

本研究旨在探讨入院时血小板与中性粒细胞比率（PNR）和血小板与淋巴细胞比率（PLR）与动脉瘤性蛛网膜下腔出血（aSAH）患者临床结局的关系。对接受 aSAH 治疗的患者进行了回顾性分析。不利的临床结果定义为 90 天时改良 Rankin 量表 (mRS) 评分为 3-6。进行接收者操作特征曲线分析以检测 PNR 和 PLR 的最佳临界值，以预测临床结果。Logistic 回归用于探索 PNR 和 PLR 与临床结果的关联。共招募了 544 名 aSAH 患者。其中，152 例（29.9%）的临床结果不佳。预测 aSAH 后 90 天临床结果的 PNR 和 PLR 的最佳临界值为 25 和 130，P  < 0.001 和 < 0.001，分别）。在多变量逻辑回归分析中，PNR <25 和 PLR ≥ 130 与 aSAH 后 90 天的不良临床结果相关（优势比 [OR]：1.81；95% 置信区间 [CI]：1.23-3.69；P = 0.018 和 OR ：1.56；95% CI：1.18–2.62；分别为 P = 0.031）。PNR 和 PLR 作为新型炎症生物标志物可以预测 aSAH 后的临床结果。PNR <22 和 PLR ≥ 130 与 aSAH 后 90 天的不良临床结果相关。